Surgical robotics company Titan Medical (CVE:TMD) is on a fundraising spree, announcing new details of a planned $22.3 million U.S. public offering after raising $11.7 million in a stock offering in Canada.
Wall Street Beat
Intuitive Surgical drops on limp Q1 prelims
Intuitive Surgical (NSDQ:ISRG) lost some Wall Street favor last night after posting dim preliminary results for its 1st quarter of 2014.
Deerfield raises $1.6B healthcare fund
Deerfield Management Co. said it raised a fund aimed at healthcare investments that’s worth $1.6 billion.
Deerfield Private Design Fund III is "designed to provide flexible private financing to healthcare companies," according to a press release.
Vital Therapies lowers the bar with 2nd IPO try
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million.
Stryker shares hit new lifetime high | MassDevice.com On Call
MASSDEVICE ON CALL — Medtech titan Stryker (NYSE:SYK) hit a new lifetime high on Friday with shares rising to $84.85 apiece.
The share spiked after a gradual incline over the course of Thursday, April 3, peaking in the late morning on Friday before settling down to close at $82.60, a 1.8% drop on the day.
TriVascular Technologies sets price range for $98M IPO
TriVascular Technologies said it could raise as much as $98 million from its planned initial public offering after setting the per-share price range at $13-$15.
That would set the top end of the 6.5-million-share offering at $97.5 million, or $84.5 million at the low end.
Biomet slashes Q3 losses, sales rise nearly 7%
Biomet said today that it slashed its 3rd-quarter losses by nearly 80% and boosted sales by 6.6% as the privately-owned orthopedics giant prepares to go back on the stock market.
Warsaw, Ind.-based Biomet posted losses of -$65.9 million on sales of $822.5 million for the 3 months ended Feb. 28. Adjusted to exclude 1-time items, profits rose 13.1% compared with the same period last year, to $107.3 million.
Analyst speculates Smith & Nephew split | Medtech Wall Street news for the week of Mar. 31, 2014
Carlyle officially wins Johnson & Johnson’s diagnostics biz for $4B
Lombard Medical sets range for $55m – $65M IPO
Lombard Medical Technologies (LON:LMT) today set the range for its forthcoming U.S. initial public offering, saying it plans to price its shares between $15 apiece and $18.
ACC 2014: Sapien XT bests CoreValve in small head-to-head study
UPDATED March 31, 2014, with comment from Medtronic